Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DNLI |
---|---|---|
09:32 ET | 10129 | 20.51 |
09:34 ET | 1131 | 20.32 |
09:36 ET | 2284 | 20.41 |
09:38 ET | 100 | 20.34 |
09:39 ET | 400 | 20.33 |
09:41 ET | 2961 | 20.405 |
09:43 ET | 1528 | 20.49 |
09:45 ET | 2315 | 20.57 |
09:48 ET | 1359 | 20.55 |
09:50 ET | 2224 | 20.6 |
09:52 ET | 1184 | 20.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Denali Therapeutics Inc | 3.0B | -21.3x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Amicus Therapeutics Inc | 3.0B | -20.3x | --- |
Genmab A/S | 17.4B | 21.7x | +22.71% |
Twist Bioscience Corp | 2.9B | -14.7x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.0x | --- |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -21.3x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.